Request Demo

Last update 04 Sep 2025

Cisplatin

Last update 04 Sep 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

CACP, CDDP, CIS-DDP

+ [24]

Target

DNA

Action

inhibitors

Mechanism

DNA inhibitors(DNA inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesDigestive System Disorders+ [9]

Active Indication

Biliary Tract NeoplasmsSquamous Cell Carcinoma of Head and NeckMalignant Pleural Mesothelioma+ [73]

Inactive Indication

Adenocarcinoma of EsophagusAdvanced Bile Duct CarcinomaAdvanced Cervical Carcinoma+ [92]

Originator Organization

HQ Specialty Pharma Corp.

Active Organization

Eli Lilly & Co.

Genentech, Inc.

Nippon Kayaku Co., Ltd.

+ [24]

Inactive Organization

EMD Serono Research & Development Institute, Inc.

Bayer AG

Pfizer Inc.

+ [12]

License Organization

Chosa Oncology AB

Eleison Pharmaceuticals, Inc.

Enkang Pharmaceutical Technology (Guangzhou) Co., Ltd.

+ [2]

Drug Highest PhaseApproved

First Approval Date

United States (19 Dec 1978),

Bladder CancerOvarian CancerTesticular Neoplasms

RegulationOrphan Drug (United States), Orphan Drug (European Union)

Structure/Sequence

Molecular FormulaCl2H6N2Pt

InChIKeyWCLAIRSNZFYZAT-UHFFFAOYSA-N

CAS Registry15663-27-1

4,064

Clinical Trials associated with Cisplatin

NCT04595981

/ WithdrawnPhase 2IIT

Chemo-embolization for Head and Neck Cancer

The study will evaluate whether adjuvant chemo-embolization increases progression free and/or overall survival relative to standard of care radiation and chemo- and/or immunotherapy in cisplatin-ineligible head and neck cancer patients with an acceptable morbidity rate.

Start Date01 May 2027

Sponsor / Collaborator

The University of Alabama at Birmingham

NCT05521997

/ Not yet recruitingPhase 2IIT

Phase II Study of Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer

Advanced cervical cancer patients treated with standard of care (SOC) chemoradiation plus glutaminase inhibition with telaglenastat (CB-839) will have increased progression-free survival (PFS) compared to historical rates for patients receiving SOC chemoradiation alone.

Start Date31 Dec 2025

Sponsor / Collaborator

Washington University School of Medicine

[+2]

NCT07141771

/ Not yet recruitingPhase 1/2IIT

An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing

Small-cell lung cancer (SCLC) has a high degree of malignancy and extremely poor prognosis, slow progress in the treatment of ES-SCLC, and a more ideal posterior therapy needs to be explored. This is an I / II, phase umbrella study to explore afterline treatment options following progression of frontline platinum-containing therapy for small cell lung cancer.
This study includes 2 parts:
Part 1 will enroll patients with end of first-line platinum-containing therapy and progression interval of less than 180 days or more of second-line therapy (no first-line relapse time required).
Part 2 will enroll patients with end of first-line platinum-containing therapy greater than 180 days.
Based on the optimal selection of patients with recurrent broad-stage small cell lung cancer with different molecular and clinical characteristics, we further explored different treatment modes suitable for different populations through umbrella cohort studies.

Start Date31 Dec 2025

Sponsor / Collaborator

Cancer Hospital Chinese Academy of Medical Sciences

100 Clinical Results associated with Cisplatin

100 Translational Medicine associated with Cisplatin

100 Patents (Medical) associated with Cisplatin

109,564

Literatures (Medical) associated with Cisplatin

01 Feb 2026·BIOMATERIALS

Article

Author: Cai, Yueming ; Fang, Chunyan ; Cai, Ying ; Lu, Yong ; Wang, Xiaoyan ; He, Cui

Cisplatin-induced acute kidney injury (AKI) epitomizes a critical barrier and paradox in cancers, where dose-limiting nephrotoxicity propelled by oxidative cascades lacks targeted interventions. This pressing clinical dilemma underscores the paramount need for kidney injury mitigation, while existing therapeutic strategies fail to achieve it due to inadequate efficacy and specificity. Here, we introduce a lactone ring-opening chemistry approach to amplify hydroxyl-driven redox modulation on gold nanorods (Au-M NRs), addressing the unmet need for precision antioxidant delivery. Specifically, the sequential functionalization of gold nanorods with thiolated polyethylene glycol amine (HS-PEG₂₀₀₀-NH₂) and 5,8-dihydroxypsoralen (5,8-DHP) triggered a structural transformation, cleaving the six-membered lactone ring of 5,8-DHP and generating an additional phenolic hydroxyl group. In cisplatin-challenged HK-2 cells, hydroxyl-enriched Au-M markedly attenuated reactive oxygen species (ROS) level and activated Keap1/Nrf2 pathway, evidenced by upregulated SOD and antioxidant Nqo1 expression alongside suppressed MDA and prooxidant Nox2 levels. SiNrf2 transfection severely abrogated the cytoprotective effects of Au-M, while Nrf2 overexpression synergistically enhanced the anti-apoptotic efficacy of Au-M in renal tubular epithelial cells. Mirroring cellular outcomes, the Au-M nanosystem elicited potent renoprotection via Nrf2-orchestrated transcriptional reprogramming in vivo, concurrently preserving the integrity and safety of healthy tissues. Critically, Au-M NRs conferred sustained protection in chronic exposure models, exhibited biocompatibility upon repeated dosing, and accelerated renal recovery, affirming their long-term therapeutic viability. This lactone-to-phenol conversion strategy pioneers a topology-guided paradigm for redox homeostasis regulation beyond AKI, establishing a transformative platform to harness natural product derivatization in combating organ-specific oxidative injury.

31 Dec 2025·Animal Cells and Systems

Parvimonas micra -polarized M2-like tumor-associated macrophages accelerate colorectal cancer development via IL-8 secretion

Article

Author: Kim, Hyung-Sik ; Yang, Ji Won ; Ahn, Ji-Su ; Seo, Yoojin ; Yu, Jeong Hyun ; Nguyen, Dang Khoa ; Park, Hee-Jeong ; Lee, Hyeon Seo ; Kim, Seong Hui ; Oh, Su-Jeong ; Kang, Min-Jung ; Lee, Yunji

Parvimonas micra (Pm), a periodontal pathogen, has been implicated in the impairment of anti-tumor responses in colorectal cancer (CRC). The tumor microenvironment in CRC involves tumor-associated macrophages (TAMs), which are pivotal in modulating tumor-associated immune responses. The polarization of TAMs towards an M2-like phenotype promotes CRC progression by suppressing the immune system. However, the mechanisms by which Pm affects the progression of CRC remain inadequately elucidated. In this study, we explored the impact of Pm infection on CRC cell characteristics, including proliferation, chemoresistance, migration, and macrophage polarization. We found that Pm-infected THP-1-derived macrophages exhibited elevated interleukin-10 levels, a well-established M2 marker. Conditioned media from Pm-treated THP-1 cells significantly enhanced CRC cell proliferation, cisplatin resistance, and migration, and interleukin-8 was identified as a key factor. Consistent with the in vitro results, an azoxymethane/dextran sodium sulfate mouse model treated with oral Pm showed accelerated CRC tumor growth. These results offer mechanistic insights into the influence of Pm infection on tumor microenvironment in CRC through M2-like macrophage polarization. The identified pathways may serve as potential targets for therapeutic interventions for CRC.

31 Dec 2025·Human Vaccines & Immunotherapeutics

Review

Author: Marchetti, Andrea ; Mollica, Veronica ; Mottaran, Angelo ; Piazza, Pietro ; Rosellini, Matteo ; Danielli, Linda ; Ricci, Costantino ; Schiavina, Riccardo ; Tassinari, Elisa ; Massari, Francesco ; Santoni, Matteo

In recent years, several clinical trials focused on the potential role of immune-checkpoint inhibitors (ICIs) in the adjuvant treatment of muscle-invasive urothelial cancer (UC). Heretofore, only the anti-programmed death protein 1 (anti-PD1) nivolumab received European Medical Agency (EMA) approval for cisplatin-unfit patients. In our work, we deeply analyzed the results of the three pivotal studies in view of the rapidly evolving therapeutic advanced UC's scenario. Furthermore, there are several ongoing research to investigate ICIs and other emerging immune agents in this setting; results are awaited. Additionally, current efforts have been made to assess the role of these agents in earlier disease settings, particularly in high-risk non-muscle-invasive bladder cancer (NMIBC). In our review, we analyzed the potential role of predictive and/or prognostic biomarkers that may improve patient selection and treatment efficacy. To conclude, we highlighted the upcoming changes that could redefine the standard of care for patients with early-stage UC.

1,245

News (Medical) associated with Cisplatin

27 Aug 2025

·www.globenewswire.com

Junshi Biosciences Announces 2025 Interim Financial Results and Provides Corporate Updates

SHANGHAI, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its 2025 interim financial results and provided corporate updates. FINANCIAL HIGHLIGHTS As of June 30, 2025, the total revenue of Junshi Biosciences was approximately RMB1,168 million for the first half of 2025, representing an increase of approximately 49% compared to 2024, driven mainly by pharmaceutical sales. In particular, the domestic sales revenue of our core product, TUOYI® (toripalimab), reached approximately RMB954 million, an increase of approximately 42% from 2024.Total research and development (“R&D”) expenses of the company were approximately RMB745 million for the first half of 2025, an approximately 36% increase compared to 2024. The higher R&D expenses were mainly due to the company’s focus on more competitive and innovative R&D pipelines and accelerated clinical development during the first half of 2024.Loss attributable to owners of the company fell to RMB413 million, representing a decrease of approximately RMB232 million or approximately 36% compared to 2024.During the first half of 2025, net cash inflow from financing activities was approximately RMB1,386 million, primarily attributable to the successful placement of the company’s new H shares on June 20, 2025, which generated a net inflow of approximately RMB940 million. This net cash inflow fully offset the cash outflows from operating and investing activities, leading to an overall increase in bank balances and cash.As of June 30, 2025, the aggregate balance of bank balances and cash and financial products of the company was approximately RMB3,490 million, ensuring a relatively stable liquidity position to support the company’s continued development. BUSINESS HIGHLIGHTS During the first half of 2025, we focused on addressing “unmet medical needs”. We have made original, innovative and breakthrough progress in the discovery, R&D and commercialization of innovative therapies and novel drugs with accelerating international development. The following are achievements and milestones we have reached: Advancements in the pipeline: the company’s innovative R&D field has expanded from monoclonal antibodies to the research and development of various drug modalities, including small molecules drugs, antibody drug conjugates (“ADC”), bi-specific or multi-specific antibodies, fusion protein, nucleic acid drugs and vaccines, as well as the exploration of next-generation innovative therapies including cancer and autoimmune diseases. The product pipelines cover five major therapeutic areas including malignant tumors, autoimmune diseases, chronic metabolic diseases, neurologic diseases and infectious diseases. A total of four drugs (TUOYI®, JUNMAIKANG, MINDEWEI and JUNSHIDA) have been commercialized, around 30 assets are undergoing clinical trials, and over 20 drug candidates are in preclinical drug development. In January 2025, the indication of TUOYI® for the treatment of unresectable or metastatic melanoma after failure of standard systemic therapy was approved by the National Medical Products Administration of China (the “NMPA”) for conversion from conditional approval to regular approval.In January 2025, the investigational new drug (“IND”) application for JS212 (a recombinant humanized epidermal growth factor receptor (“EGFR”) and human epidermal growth factor receptor 3 [“HER3”] bispecific ADC) was accepted by the NMPA and subsequently approved in March 2025.In January 2025, the indication of MINDEWEI for the treatment of adult patients with mild to moderate coronavirus disease 2019 (“COVID-19”) was approved by the NMPA for conversion from conditional approval to regular approval.In January 2025, the New Chemical Entity (“NCE”) application for 1) toripalimab in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma (“NPC”) and 2) toripalimab, as a single agent, for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after platinum-containing chemotherapy was approved by the Therapeutic Goods Administration of the Australian Government Department of Health and Aged Care (the “TGA”). Toripalimab became the first immuno-oncology treatment for NPC in Australia.In February 2025, the IND application for JS213 (a PD-1 and interleukin-2 (“IL-2”) bifunctional antibody fusion protein) was approved by the NMPA.In March 2025, the supplemental new drug application (the “sNDA”) for TUOYI® in combination with bevacizumab for the first-line treatment for patients with unresectable or metastatic hepatocellular carcinoma (“HCC”) was approved by the NMPA.In March 2025, the new drug application (the “NDA”) for toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic NPC was approved by the Singapore Health Sciences Authority (the “HSA”). Toripalimab became the first approved immuno-oncology treatment for NPC in Singapore.In April 2025, the sNDA for TUOYI® for the first-line treatment of unresectable or metastatic melanoma was approved by the NMPA. This was toripalimab’s 12th indication in the Chinese Mainland.In May 2025, the two sNDAs for the ongericimab injection (a recombinant humanized anti-PCSK9 monoclonal antibody injection, trade name: JUNSHIDA) for: 1) adult patients with heterozygous familial hypercholesterolemia (“HeFH”); 2) alone or in combination with ezetimibe, in adult patients with non-familial hypercholesterolemia and mixed dyslipidemia who are statin-intolerant or statins contraindicated, were approved by the NMPA. Ongericimab became the first domestic PCSK9-targeted drug approved for statin-intolerant patients.In June 2025, the IND application for the JT118 injection (“JT118”) was accepted. JT118 is a “two-in-one” recombinant protein vaccine composed of a tandem fusion of monkeypox virus antigens A35 (an extracellular enveloped virus antigen) and M1 (an intracellular mature virus antigen), and is intended mainly for the prevention of monkeypox virus infection.In June 2025, the indications of toripalimab for the first-line treatment of NPC and the first-line treatment of esophageal squamous cell carcinoma (“ESCC”) were officially approved for marketing in the United Arab Emirates (the “UAE”) and Kuwait. External collaborations In January 2025, TopAlliance Biosciences, a wholly-owned subsidiary of the company, entered into a distribution and marketing agreement with LEO Pharma. TopAlliance Biosciences will grant LEO Pharma the exclusive right to store, distribute, promote, market and sell toripalimab in all current member states and any future member states of the European Union (the “EU”) and the European Economic Area (the “EEA”), Switzerland as well as the United Kingdom (the “UK”) (the “Territory”). LEO Pharma shall pay TopAlliance Biosciences an upfront payment of EUR15 million, milestone payment(s) for any subsequent approved indication(s) for toripalimab in the Territory, and a revenue share of a double-digit percentage on the net sales of toripalimab throughout the Territory. Business operations In June 2025, the company convened the 2024 annual general meeting, at which all resolutions were considered and approved.In June 2025, the company completed the placing of new H shares under general mandate (the “Placing”), pursuant to which an aggregate of 41,000,000 H shares (the “Placing Shares”) were successfully allotted and issued at HK$25.35 per H share. The net proceeds (after deduction of commissions and estimated expenses) amounted to approximately HK$1,026 million, which will be used for innovative drug development and general corporate purposes such as replenishment of working capital. About Junshi Biosciences Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Five of the company’s products have received approvals in China and international markets, one of which is toripalimab, China’s first domestically produced and independently developed anti-PD-1 monoclonal antibody. Toripalimab has been approved in 40 countries and regions including China, the US, and Europe. During the COVID-19 pandemic, Junshi Biosciences actively shouldered the social responsibilities of a Chinese pharmaceutical company through its involvement in developing etesevimab, MINDEWEI®, and other novel therapies for the prevention and treatment of COVID-19. With a mission of “providing patients with world-class, trustworthy, affordable, and innovative drugs,” Junshi Biosciences is “In China, For Global.” At present, the company boasts approximately 2,500 employees in the United States (Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc.). For more information, please visit: http://www.junshipharma.com. Junshi Biosciences Contact InformationIR Team:Junshi Biosciencesinfo@junshipharma.com+ 86 021-6105 8800 PR Team:Junshi BiosciencesZhi Lizhi_li@junshipharma.com+ 86 021-6105 8800

Drug ApprovalFinancial StatementLicense out/inVaccinePhase 1

21 Aug 2025

·www.pharmaceutical-technology.com

Padcev-Keytruda combo approved for NHS use in mUC

The National Institute for Health and Care Excellence (NICE) has recommended a combination of Padcev and Keytruda for the treatment of metastatic urothelial carcinoma (mUC). Image credit: santypan via ShutterStock.com. The UK’s National Institute for Health and Care Excellence (NICE) has recommended a new combination regimen in metastatic urothelial carcinoma (mUC) for use by the National Health Service (NHS). This means that patients across the UK will now have access to a dual-pronged, targeted treatment approach, which combines Astellas Pharma and Pfizer’s antibody-drug conjugate (ADC) Padcev (enfortumab vedotin) with MSD’s Keytruda (pembrolizumab). Padcev and Keytruda were made available to patients through the signing of commercial deals between NHS England and both Astellas and MSD. These agreements brought prices of the drug down, allowing NICE to deem the treatment “cost-effective”. The combination was approved as a therapeutic regimen by the US Food and Drug Administration (FDA) in December 2023, which the European Commission (EC) and Medicines and Healthcare products Regulatory Agency (MHRA) echoed, giving the two drugs the go-ahead in September and October 2024, respectively. Padcev-Keytruda is now the standard of care (SoC) in first-line mUC treatment due to the positive results of the Phase III EV-302 trial (NCT04223856), which found that the cancer-fighting duo could reduce the risk of disease progression or death by 55%. Following its introduction to the bladder cancer market, the combination will join Bristol Myers Squibb’s (BMS) blockbuster PD-1 blocker Opdivo (nivolumab), which is available through the NHS as an adjuvant treatment to surgery for high-risk, muscle-invasive bladder cancer (MIBC) in chemotherapy-ineligible patients. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence In the US, the drug is generally prescribed in MIBC patients alongside cisplatin and gemcitabine for first-line treatment of MIBC. However, a report by GlobalData predicts that Padcev-Keytruda will absorb a significant proportion of Opdivo’s market share moving forward. This will likely be driven by the results of the Phase III EV-303/KEYNOTE-905 trial (NCT03924895), which found that the combination extended survival in cisplatin-ineligible patients – an effect that was observed before and after surgical cystectomy. The combination’s strong efficacy profile only further bolsters the current success of Keytruda, which has dominated the oncology market – so much so that it was the best-selling drug of 2024, raking in $29.5bn for MSD. In the short term, analysts at GlobalData forecast that the drug’s sales will continue to climb, peaking at $35.7bn in 2027. However, sky-high sales of the PD-1 inhibitor may soon crash back down to earth, as the key US patents covering its exclusivity are set to expire in 2028. Following this, Keytruda will face significant competition from generics, with GlobalData’s analysts predicting that income from the drug will drop by 53% to $16.7bn in 2031. To try and curb this impact, MSD has developed a subcutaneous form of Keytruda, which is currently under regulatory review with the FDA. The regulator is expected to make a final decision on the drug by 23 September 2025. Meanwhile, the longer-term growth outlook for Padcev is positive, as GlobalData’s analysts forecast that the drug’s sales are set to bring in $6.3bn by 2031. Pfizer and Astellas are also conducting trials to widen Padcev’s potential, with 27 clinical trials currently exploring the drug’s efficacy in bladder and urinary tract cancers. ADC content on Pharmaceutical Technology is supported by Syngene . Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

Phase 3Drug ApprovalClinical Result

19 Aug 2025

·www.prnewswire.com

Nature Medicine Publishes Results of Phase II Study of Sacituzumab Tirumotecan Plus Tagitanlimab as First-Line Therapy for NSCLC

CHENGDU, China, Aug. 19, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990) announced that clinical data from a Phase II study evaluating novel TROP2 antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) in combination with PD-L1 monoclonal antibody (mAb) tagitanlimab for the first-line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) have been published in Nature Medicine (Impact Factor: 58.7). The publication highlighted initial findings from the Phase II OptiTROP-Lung01 study, evaluating the efficacy and safety results of sac-TMT in combination with tagitanlimab as a first-line treatment of advanced or metastatic NSCLC patients without actionable genomic alterations. The study was led by Prof. Zhang Li's team at the Center for Cancer Prevention and Control, Sun Yat-sen University, China. Patients in Cohort 1A received sac-TMT (5 mg/kg, Q3W) plus tagitanlimab (1200 mg, Q3W) in a three-week cycle, while patients in Cohort 1B were treated with sac-TMT (5 mg/kg, Q2W) plus tagitanlimab (900 mg, Q2W) in a four-week cycle. Patients received sac-TMT in combination with tagitanlimab in a non-randomized manner until disease progression or unacceptable toxicity. Median follow-ups for Cohort 1A and Cohort 1B were 19.3 months and 13.0 months, respectively (Data cutoff date: May 27, 2024). The study results demonstrated promising anti-tumor activity, and manageable safety of sac-TMT in combination with tagitanlimab as a first-line treatment for advanced or metastatic NSCLC patients. A total of 40 patients in Cohort 1A and 63 patients in Cohort 1B were included in the full analysis set (FAS) for efficacy assessment. In Cohort 1A and Cohort 1B, respectively, the confirmed objective response rates (ORRs) were 40.0% (95% CI: 24.9–56.7) and 66.7% (95% CI: 53.7–78.0), and the ORRs were: 44.4% and 64.7% among patients with non-squamous carcinoma, 36.4% and 69.0% with squamous carcinoma; 41.7% and 57.1% among patients with PD-L1 tumor proportion score (TPS) <1%; 38.5% and 63.2% for TPS 1–49%; 40.0% and 78.3% for TPS ≥50%. The median progression-free survival (mPFS) for Cohort 1A was 15.4 months (95% CI: 6.7–17.9) and not reached (95% CI: 9.6–NE) for Cohort 1B. The most common grade ≥3 treatment-related adverse events (TRAEs) for both Cohorts 1A and 1B were decreased neutrophil count, decreased white blood cell count and anemia. No treatment-related deaths were observed. Subgroup analyses showed consistent efficacy across PD-L1 and TROP2 expression levels, as well as in both squamous and non-squamous histological subtypes. Dr. Michael Ge, CEO of Kelun-Biotech, commented: "The OptiTROP-Lung01 study supports the promising efficacy and safety of sacituzumab tirumotecan in combination with tagitanlimab as a first-line treatment for patients with advanced NSCLC. The results were observed across PD-L1/TROP2 expression levels and histological subtypes and support the advancement potential of sac-TMT from later-line to front-line therapy. The publication of results from several studies in top-tier international journals reflects the recognition of our innovation-driven development strategy. We will continue to work to address critical clinical challenges and unmet medical needs, striving to deliver more therapeutic options and improve quality of life for patients." About sac-TMT Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic HR+/HER2- BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the CDE, and were included in the priority review and approval process. As of today, the Company has initiated 9 registrational clinical studies in China. MSD has initiated 14 ongoing Phase III global clinical studies of sac-TMT as a monotherapy or with pembrolizumab[1] or other agents for several types of cancer. These studies are sponsored and led by MSD. About Tagitanlimab Tagitanlimab is the first PD-L1 mAb globally to receive authorization for the first-line treatment of NPC. Previously, the NMPA has approved the marketing in China of tagitanlimab used in combination with cisplatin and gemcitabine for the first-line treatment of patients with R/M NPC and monotherapy for the treatment of patients with recurrent or metastatic NPC who have failed after prior 2L+ chemotherapy, respectively. About Kelun-Biotech Kelun-Biotech（6990.HK）is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit . Media: [email protected] SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultPhase 2Phase 3Drug ApprovalPriority Review

100 Deals associated with Cisplatin

External Link

KEGG	Wiki	ATC	Drug Bank
D00275	Cisplatin	L01XA01	DB00515

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Biliary Tract Neoplasms	Japan	Nippon Kayaku Co., Ltd.	22 Feb 2012
Squamous Cell Carcinoma of Head and Neck	Brazil	Libbs Farmacêutica Ltda.	22 Jan 2007
Malignant Pleural Mesothelioma	Japan	Nippon Kayaku Co., Ltd.	04 Jan 2007
Childhood Malignant Solid Neoplasm	Japan	Nippon Kayaku Co., Ltd.	15 Sep 2005
Lymphoma	Japan	Nippon Kayaku Co., Ltd.	15 Sep 2005
Bone Cancer	Japan	Nippon Kayaku Co., Ltd.	14 Feb 2005
Endometrial Carcinoma	Japan	Nippon Kayaku Co., Ltd.	14 Feb 2005
Germinoma	Japan	Nippon Kayaku Co., Ltd.	31 May 2004
Hepatocellular Carcinoma	Japan	Nippon Kayaku Co., Ltd.	29 Jan 2004
Osteosarcoma	Japan	Nippon Kayaku Co., Ltd.	21 Dec 1999
Small Cell Lung Cancer	Japan	Nippon Kayaku Co., Ltd.	21 Dec 1999
Solid tumor	China	Dezhou Bocheng Pharmaceutical Technology Co., Ltd.	01 Jan 1995
Solid tumor	China	Yunnan Phytopharmaceutical Co. Ltd.	01 Jan 1995
Solid tumor	China	Dezhou Deyao Intelligent Pharmacy Co., Ltd.	01 Jan 1995
Solid tumor	China	Qilu Pharmaceutical Co., Ltd.	01 Jan 1995
Solid tumor	China	Kunming Guiyan Pharmaceutical Co., Ltd.	01 Jan 1995
Stomach Cancer	Japan	Nippon Kayaku Co., Ltd.	03 Jun 1990
Esophageal Carcinoma	Japan	Nippon Kayaku Co., Ltd.	30 May 1988
Neuroblastoma	Japan	Nippon Kayaku Co., Ltd.	30 May 1988
Uterine Cervical Cancer	Japan	Nippon Kayaku Co., Ltd.	30 May 1988

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Muscle Invasive Bladder Carcinoma	Phase 3	Australia	AstraZeneca PLC	15 May 2025
Muscle Invasive Bladder Carcinoma	Phase 3	Brazil	AstraZeneca PLC	15 May 2025
Muscle Invasive Bladder Carcinoma	Phase 3	Canada	AstraZeneca PLC	15 May 2025
Muscle Invasive Bladder Carcinoma	Phase 3	France	AstraZeneca PLC	15 May 2025
Muscle Invasive Bladder Carcinoma	Phase 3	Italy	AstraZeneca PLC	15 May 2025
Muscle Invasive Bladder Carcinoma	Phase 3	Netherlands	AstraZeneca PLC	15 May 2025
Muscle Invasive Bladder Carcinoma	Phase 3	Spain	AstraZeneca PLC	15 May 2025
Fallopian Tube High Grade Serous Adenocarcinoma	Phase 3	United States	GSK Plc	08 Mar 2024
Primary peritoneal carcinoma	Phase 3	United States	GSK Plc	08 Mar 2024
Lung Cancer	Phase 3	United States	Eleison Pharmaceuticals, Inc.	01 Feb 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04692051 (ChiCTR380004040, Pubmed \| BMC Cancer)	Phase 2	Advanced biliary tract cancer First line	75	Nab-paclitaxel plus cisplatin	vejljprhng(ojoxegdarg) = tnzobeyetc zdiuvbsbwb (hesewhqquk, 5.4 - 14.0) View more	Non-inferior	16 Aug 2025
				gemcitabine plus cisplatin	vejljprhng(ojoxegdarg) = lgfbgoffqy zdiuvbsbwb (hesewhqquk, 3.9 - 10.1) View more
NCT03579771 (NEO-GAP, CTgov)	Phase 2	Intrahepatic Cholangiocarcinoma	30	Nab-paclitaxel+Gemcitabine+cisplatin	eowtgykwmo = dkdqjxazkt kasumrofrn (whnrrdjgzr, azbeertkdx - vqchfcdoxh) View more	-	15 Aug 2025
NCT03366415 (Pubmed \| JAMA Oncol) Manual	Phase 3	Nasopharyngeal Carcinoma	420	Gemcitabine + cisplatin (SCRT group)	wxrfvlfjrs(evonafaomb) = nrphmwomjt mtjzxsjtkl (ylkmkbvfhs, 78.6 - 88.8)	Non-inferior	24 Jul 2025
				GemcitabineGemcitabine + cisplatin (IC plus CCRT group)	wxrfvlfjrs(evonafaomb) = wyenacsxmb mtjzxsjtkl (ylkmkbvfhs, 74.0 - 85.0)
NCT03734692 (CTgov)	Phase 1/2	Recurrent ovarian cancer	24	cisplatin+Rintatolimod+Pembrolizumab	fcjxafxoeu = ykzixugxfb euoaxhhagl (flregalqjt, mmlpjzsntn - tdpmwbdhai) View more	-	20 Jul 2025
NCT03260712 (ESMO_GI2025) Manual	Phase 2	Advanced biliary tract cancer First line	50	Cisplatin/gemcitabine + Pembrolizumab	xfaduhmepi(qmpcbqmhly) = fpwgzuzryr iszawwqxnt (rijdclvsee, 52 - 70) View more	Positive	03 Jul 2025
				CisplatinCisplatin/gemcitabine + Pembrolizumab (AJCC Stage II/III)	mhczbrusld(lpmbdpmdnx) = phaaxcdjex xgpstmdzsq (ptzauulqrg, 8.3 - NE) View more
NCT03811002 (NRG-LU005, CTgov)	Phase 3	Small cell lung cancer limited stage	544	Intensity-Modulated Radiation Therapy+Etoposide+Carboplatin+cisplatin (Arm I (Chemotherapy, Radiation Therapy))	qoehkjkpyn(kenjdgdhkx) = xotioppouf yzglvzrcah (gtwrkkmobi, ytcsruvalo - gzqbjjxwcu) View more	-	12 Jun 2025
				Intensity-Modulated Radiation Therapy+Etoposide+Carboplatin+cisplatin+Atezolizumab (Arm II (Chemotherapy, Radiation Therapy, Atezolizumab))	qoehkjkpyn(kenjdgdhkx) = fuivrqwjlx yzglvzrcah (gtwrkkmobi, vceafpqzkv - xdkhfrpcxu) View more
NCT02262325 (CTgov)	Phase 2	Non-small cell lung cancer stage IIIA \| Non-small cell lung cancer stage IIIB \| Recurrent Non-Small Cell Lung Cancer ... View more	21	3-dimensional conformal radiation therapy+etoposide+cisplatin	zwrgtkoxmq = uwbjzjabto vtngeluzkr (djztjaauwf, avgpmoutxx - xieuwljtzv) View more	-	12 Jun 2025
ASCO2025	Not Applicable	Advanced biliary tract cancer First line	45	Cisplatin, Gemcitabine, Durvalumab	kndcsdnafb(rgeiowfrmw) = hsatsdqybn kddcglcgyy (xkztwvcppf ) View more	Positive	30 May 2025
NCT03944915 (DEPEND, CTgov)	Phase 2	Human Papillomavirus Infection \| Human Papillomavirus-Related Squamous Cell Carcinoma \| Locally Advanced Head and Neck Squamous Cell Carcinoma	35	Nivolumab+Carboplatin+Paclitaxel (Standard Chemotherapy)	ackzcwlrja = tmkckihgyu dqhpqudtrp (logbcmiuvz, fjfkzzhkfg - camdioggzk) View more	-	11 May 2025
				Radiation+Filgrastim Injection+Paclitaxel+Hydroxyurea Pill+cisplatin+5-fluorouracil (De-escalated Chemotherapy)	ackzcwlrja = kxummvgyex dqhpqudtrp (logbcmiuvz, ckkznhyble - qctqgbzatr) View more
NCT02807181 (SIRCCA, CTgov)	Phase 2/3	Unresectable Intrahepatic Cholangiocarcinoma	89	gemcitabine+Cisplatin (Chemotherapy (Cisplatin-Gemcitabine))	jlyypexurw(zopvodzccd) = mcpsoqceoi arnxreovit (wyorhbyvvo, bhpupewekp - cfqofcyoeu) View more	-	09 May 2025
				Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)+gemcitabine+Cisplatin (Radiation: SIRT + Chemotherapy (Cisplatin-Gemcitabine))	jlyypexurw(zopvodzccd) = dtqatnomgx arnxreovit (wyorhbyvvo, ttwbgzaxde - ghbrdqlirj) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis